Brentuximab Vedotin with Adriamycin, Vinblastine and Dacarbazine for Patients Aged 18-59 Years with Untreated Advanced-stage Classical Hodgkin Lymphoma: a Real-life Experience

Inclusion Criteria

• •histological diagnosis of previously untreated c-HL
• •stage III or IV at diagnosis
• •treatment with at least one cycle of therapy according to the Brentuximab Vedotin + AVD regimen
• •age between 18 and 59 years
• •ECOG at diagnosis: PS 0-3
• •negative HIV test
• •follow up from the end of treatment \>24 months All diagnoses are made according to the WHO classification of Lymphomas.